Advertisement

Medicinal Chemistry Research

, Volume 26, Issue 11, pp 3015–3025 | Cite as

Novel L-arginine derivatives as aminopeptidase N inhibitors: design, chemistry, and pharmacological evaluation

  • Jiajia Mou
  • Yepeng Luan
  • Danghui Chen
  • Qiang Wang
Original Research

Abstract

Considering the important roles played in tumor, aminopeptidase N has been an appealing target for anti-tumor drug development. Here, a serial of novel aminopeptidase N inhibitors with L-arginine scaffold were designed, synthesized and evaluated for aminopeptidase N inhibitory activities. The preliminary anti-enzyme activity assay demonstrated that compounds 5e, 5h, 11e, 11g, and 11h showed comparable activities with the positive control bestatin, an approved aminopeptidase N inhibitor. In vitro anti-proliferation assay, compound 5f showed excellent activities against four kinds of tumor cells which overexpress aminopeptidase N. In vivo anti-metastasis assay, compounds 5f and 11g exhibited better activities than bestatin. So 5f and 11g should be lead compounds as novel aminopeptidase N inhibitors for further development.

Keywords

L-arginine derivatives Aminopeptidase N Synthesis Anti-enzyme activity Anti-proliferation activity Anti-metastasis activity 

Notes

Acknowledgements

This work was supported by National Nature Science Foundation of China (Grant No. 21502142) and Tianjin Research Program of Application Foundation and Advanced Technology (No.15JCQNJC14100) and Program for Changjiang Scholars and Innovative Research Team in University (IRT_14R41). The authors thank South-central University for Nationalities for supporting of CADD softwares.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

References

  1. Addlagatta A, Gay L, Matthews BW (2008) Structural basis for the unusual specificity of Escherichia coli aminopeptidase N. Biochemistry 47:5303–5311CrossRefPubMedGoogle Scholar
  2. Aoyagi T, Tobe H, Kojima F, Hamada M, Takeuchi T, Umezawa H (1978) Amastatin, an inhibitor of aminopeptidase A, produced by actinomycetes. J Antibiot 31:636–638CrossRefPubMedGoogle Scholar
  3. Aoyagi T, Yoshida S, Nakamura Y, Shigihara Y, Hamada M, Takeuchi T (1990) Probestin, a new inhibitor of amino- peptidase M, produced by Streptomyces azureus MH663-2F6. I. Taxonomy, production, isolation, physico-chemical properties and biological activities. J Antibiot 43:143–148CrossRefPubMedGoogle Scholar
  4. Bank U, Bohr UR, Reinhold D, Lendeckel U, Ansorge S, Malfertheiner P, Tager M (2008) Inflammatory bowel diseases: multiple benefits from therapy with dipeptidyl- and alanyl-aminopeptidases inhibitors. Front Biosci 13:3699–3713CrossRefPubMedGoogle Scholar
  5. Fujii H, Nakajima M, Saiki I, Yoneda J, Azuma I, Tsuruo T (1995) Human melanoma invasion and metastasis enhancement by high expression of aminopeptidase N/CD13. Clin Exp Metastsis 13:337–344Google Scholar
  6. Fukasawa K, Fujii H, Saitoh Y, Koizumi K, Aozuka Y, Sekine K, Yamada M, Saiki I, Nishikawa K (2006) Aminopeptidase N (APN/CD13) is selectively expressed in vascular endothelial cells and plays multiple roles in angiogenesis. Cancer lett 243:135–143CrossRefPubMedGoogle Scholar
  7. Ishii K, Usui S, Sugimura Y, Yoshida S, Hioki T, Tatematsu M, Yamamoto H, Hirano K (2001) Aminopeptidase N regulated by zinc in human prostate participates in tumor cell invasion. Int J Cancer 92:49–54CrossRefPubMedGoogle Scholar
  8. Ito K, Nakajima Y, Onohara Y, Takeo M, Nakashima K, Matsubara F, Ito T, Yoshimoto T (2006) Crystal structure of aminopeptidase N (proteobacteria alanyl aminopeptidase) from Escherichia coli and conformational change of methionine 260 involved in substrate recognition. J Biol Chem 281:33664–33676CrossRefPubMedGoogle Scholar
  9. Lejczak B, Kafarski P, Zygmunt J (1989) Inhibition of aminopeptidases by aminophosphonates. Biochemistry 28:3549–3555CrossRefPubMedGoogle Scholar
  10. Li Y, Xu W (2004) Design, synthesis, and activity of caffeoyl pyrrolidine derivatives as potential gelatinase inhibitors. Bioorg Med Chem 12:5171–5180CrossRefPubMedGoogle Scholar
  11. Minaosorio P (2008) The moonlighting enzyme CD13: old and new functions to target. Trends Mol Med 14:361–371CrossRefGoogle Scholar
  12. Mou J, Fang H, Jing F, Wang Q, Liu Y, Zhu H, Xu W (2009) Design, synthesis and primary activity evaluation of L-arginine derivatives as amino-peptidase N/CD13 inhibitors. Bioorg Med Chem 17:4666–4673CrossRefPubMedGoogle Scholar
  13. Mou J, Fang H, Liu Y, Shang L, Wang Q, Zhang L, Xu W (2010) Design, synthesis and primary activity assay of bi- or tri-peptide analogs with the scaffold L-arginine as amino-peptidase N/CD13 inhibitors. Bioorg Med Chem 18:887–895CrossRefPubMedGoogle Scholar
  14. Rahbar A, Boström L, Söderbergnaucler C (2006) Detection of cytotoxic CD13- specific autoantibodies in sera from patients with ulcerative colitis and Crohn’s disease. J Autoimmun 26:155–164CrossRefPubMedGoogle Scholar
  15. Reinhold D, Bank U, Täer M, Ansorge S, Wrenger S, Thielitz A, Lendeckel U, Faust J, Neubert K, Brocke S (2008) DPIV/CD26, APN/CD13 and related enzymes as regulators of T cell immunity: implications for experimental encephalomyelitis and multiple sclerosisD. Front Biosci 13:2356–2363CrossRefPubMedGoogle Scholar
  16. Shimazawa R, Takayama H, Fujimoto Y, Komoda M, Dodo K, Yamasaki R, Shirai R, Koiso Y, Miyata K, Kato F, Kato M, Miyachi H, Hashimoto Y (1999) Novel small molecule nonpeptide aminopeptidase n inhibitors with a cyclic imide skeleton. J Enzym Inhib Med Chem 14:259–275Google Scholar
  17. Shimizu T, Tani K, Hase K, Ogawa H, Huang L, Shinomiya F, Sone S (2002) CD13/aminopeptidase N-induced lymphocyte involvement in inflamed joints of patients with rheumatoid arthritis. Arthritis Rheum 46:2330–2338CrossRefPubMedGoogle Scholar
  18. Tomanek RJ, Schatteman GC (2000) Angiogenesis: new insights and therapeutic potential. Anat Rec 261:126–135CrossRefPubMedGoogle Scholar
  19. Wang Q, Chen M, Zhu H, Zhang J, Fang H, Wang B, Xu W (2008) Design, synthesis and QSAR studies of novel lysine derives as amino-peptidase N/ CD13 inhibitors. Bioorg Med Chem 16:5473–5481CrossRefPubMedGoogle Scholar
  20. Xu W, Li Q (2005) Progress in the development of aminopeptidase N (APN/ CD13) inhibitors. Curr Med Chem Anti-Cancer Agents 5:281–301CrossRefPubMedGoogle Scholar
  21. Yamashita M, Kajiyama H, Terauchi M, Shibata K, Ino K, Nawa A, Mizutani S, Kikkawa F (2007) Involvement of aminopeptidase N in enhanced chemosensitivity to paclitaxel in ovarian carcinoma in vitro and in vivo. Int J Cancer 120:2243–2250CrossRefPubMedGoogle Scholar
  22. Zhang Y, Feng J, Jia Y, Wang X, Zhang L, Liu C, Fang H, Xu W (2011) Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities. J Med Chem 54:2823–2838CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • Jiajia Mou
    • 1
  • Yepeng Luan
    • 2
  • Danghui Chen
    • 1
  • Qiang Wang
    • 3
  1. 1.Department of Medicinal ChemistrySchool of Chinese Materia Medica, Tianjin University of Traditional Chinese MedicineTianjinChina
  2. 2.Department of Medicinal ChemistryCollege of Pharmacy, Qingdao UniversityQingdaoChina
  3. 3.College of PharmacySouth-central University for NationalitiesWuhanChina

Personalised recommendations